Can a 3-Day drug cocktail rejuvenate kidney patients?

NCT ID NCT02848131

ENROLLING_BY_INVITATION Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a short course of two drugs, dasatinib and quercetin, can clear senescent (aging) cells in people with chronic kidney disease. The goal is to see if this reduces frailty and improves stem cell function. Thirty participants aged 40-80 with moderate-to-severe kidney disease will take the drugs for 3 days and be monitored for changes in cell health and physical ability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dasatinib and Quercetin
What this could lead to: If it works, this could point toward a treatment that reduces frailty and improves physical function in people with chronic kidney disease.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply broadly. The drugs are taken for just 3 days, so any benefits may be short-lived or not occur at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.